Published in Acta Pharmacol Sin on February 27, 2017
Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol (2006) 9.58
Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol (2000) 7.17
Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation (1991) 4.65
Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation (2001) 3.21
PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation. Cell Metab (2011) 2.94
On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1. Genes Dev (2012) 2.82
Sirtuin functions in health and disease. Mol Endocrinol (2007) 2.38
Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7). Am J Physiol Heart Circ Physiol (2006) 2.17
Angiotensin II type 2 receptor is essential for left ventricular hypertrophy and cardiac fibrosis in chronic angiotensin II-induced hypertension. Circulation (2001) 2.14
Intra-mitochondrial poly(ADP-ribosylation) contributes to NAD+ depletion and cell death induced by oxidative stress. J Biol Chem (2003) 2.04
Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. Proc Natl Acad Sci U S A (2000) 1.93
Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. Exp Physiol (2005) 1.85
Resveratrol prevents the development of pathological cardiac hypertrophy and contractile dysfunction in the SHR without lowering blood pressure. Am J Hypertens (2009) 1.82
SIRT1 promotes cell survival under stress by deacetylation-dependent deactivation of poly(ADP-ribose) polymerase 1. Mol Cell Biol (2009) 1.79
Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure. J Pharmacol Exp Ther (2002) 1.69
Poly(ADP-Ribose) polymerase inhibition reduces reperfusion injury after heart transplantation. Circ Res (2002) 1.23
Poly(ADP-ribose) polymerase-1-deficient mice are protected from angiotensin II-induced cardiac hypertrophy. Am J Physiol Heart Circ Physiol (2006) 1.20
Are poly(ADP-ribosyl)ation by PARP-1 and deacetylation by Sir2 linked? Bioessays (2003) 1.17
Protective effects of sirtuins in cardiovascular diseases: from bench to bedside. Eur Heart J (2015) 1.11
Poly (ADP-ribose) polymerase-1 is a key mediator of liver inflammation and fibrosis. Hepatology (2014) 1.09
Mitochondrial poly(ADP-ribosylation): from old data to new perspectives. FASEB J (2004) 1.06
PARP inhibition delays transition of hypertensive cardiopathy to heart failure in spontaneously hypertensive rats. Cardiovasc Res (2009) 0.99
Increased expression of poly(ADP-ribose) polymerase-1 contributes to caspase-independent myocyte cell death during heart failure. Am J Physiol Heart Circ Physiol (2004) 0.99
PARP-1 suppresses adiponectin expression through poly(ADP-ribosyl)ation of PPAR gamma in cardiac fibroblasts. Cardiovasc Res (2008) 0.97
Sirtuin 6 protects cardiomyocytes from hypertrophy in vitro via inhibition of NF-κB-dependent transcriptional activity. Br J Pharmacol (2013) 0.96
Angiotensin II promotes poly(ADP-ribosyl)ation of c-Jun/c-Fos in cardiac fibroblasts. J Mol Cell Cardiol (2008) 0.94
Effect of 3-aminobenzamide, PARP inhibitor, on matrix metalloproteinase-9 level in plasma and brain of ischemic stroke model. Toxicology (2005) 0.93
Poly(ADP-ribose) polymerase-1 inhibitor 3-aminobenzamide enhances apoptosis induction by platinum complexes in cisplatin-resistant tumor cells. Med Chem (2006) 0.90
PARP inhibition prevents postinfarction myocardial remodeling and heart failure via the protein kinase C/glycogen synthase kinase-3beta pathway. J Mol Cell Cardiol (2006) 0.90
Proteomic analysis of hypertrophied myocardial protein patterns in renovascularly hypertensive and spontaneously hypertensive rats. J Proteome Res (2006) 0.88
In vitro poly(ADP-ribosyl)ation of seminal ribonuclease. J Biol Chem (1986) 0.87
Regulation of myofibroblast differentiation by poly(ADP-ribose) polymerase 1. Am J Pathol (2013) 0.86
Poly(ADP-ribose) polymerase 1 (PARP1) in atherosclerosis: from molecular mechanisms to therapeutic implications. Med Res Rev (2013) 0.83
Possible role of poly(ADP-ribose) polymerase in pathological and physiological cardiac hypertrophy. Methods Find Exp Clin Pharmacol (2006) 0.83
AG-690/11026014, a novel PARP-1 inhibitor, protects cardiomyocytes from AngII-induced hypertrophy. Mol Cell Endocrinol (2014) 0.82
Role of Sirtuins in Regulating Pathophysiology of the Heart. Trends Endocrinol Metab (2016) 0.80
SIRT1 activation attenuates diastolic dysfunction by reducing cardiac fibrosis in a model of anthracycline cardiomyopathy. Int J Cardiol (2015) 0.79
Inhibition of PARP prevents angiotensin II-induced aortic fibrosis in rats. Int J Cardiol (2012) 0.77